ZYPREXA Complicated Mood ProjectSimilarities to the Past (De ja Vu)

- Zyprexa PCP is in similar position to Redacted PCP at launch
 - PCPs uncomfortable/not well trained on recognizing, diagnosing and tx depression
 - PCPs typically referred to a psychiatrist vs. treating with older meds
 - Undertreatment/misdiagnosis was well documented (Wells/Rand study)
 - Managed care organizations were opposed to the newer, more expensive SSRIs being used (not considered the standard of care at the time) and budget "busters"
- Zyprexa molecule plan indicates stretch target (Redacted incremental, Redacted in PC)
- Competition looming with relaunch of Geodon and increased Seroquel/Risperdal PCP focus
- Zyprexa PCP offers best growth opportunity to accomplish/exceed stretch target

ZYPREXA Complicated Mood Project

Market Research on Use of Zyprexa in Complicated Mood Disorders*

(awaiting Zohar Porat)

 Better opportunity/chance of ownership with complicated mood versus elderly patient

*Defined as bipolar, treatment resistant depression ("burned out depression")

ZYPREXA Complicated Mood ProjectProposal for Zyprexa Complicated Mood Project

- Theory that Zyprexa PCP has untapped growth potential in complicated mood patient
- Due to undetermined impact/theory on Zyprexa Sales Performance, proposal is to pilot test a campaign on Recognition/Diagnosis/Treatment of Complicated Mood Patient in the PCP office

Methodology: Pilor test via Nedical Education Campaigne • Pilot would include the following: run run . Lospitals

- Selection of three districts for implementation (Nashville, Tulsa, Birmingham)
- Timing would be Q1 of 2002 · local Advocacy croups
- Involvement of Brand group with advisors to develop campaign to educate PCP on RDT Complicated Mood Disorders RCC's
- Venue would be Territory/District programs (road show format)
- Case study format could increase draw

add nacket Persearch

ZYPREXA Complicated Mood Project

Tentative Timeline

12/12	- Taylor approval
12/13	- Jordan approval?
12/14	- Follow up conference call with Lilly participants (Steering Committee including Medical)
12/14	- Selection/contact advisory panel members ¬ (Kabinoff), Rupe, Manning, Bales)
1/3 mm 0 A	- Steering Committee meeting (Atlanta/Indianapolis)
1/9	- Advisory planning meeting (Indianapolis)
1/10 - 2/15	- Development of slides/monographs (if time/budget allows)
3/1	 Rollout of Complicated Mood RDT Campaign (road show approach if advisors/speakers allow)
4/8	- Reconvene Steering Committee for evaluation and next step decisions

Steering

ZYPREXA Complicated Mood Project

Potential Issues/Questions to be Answered

Must get a handle on weight gain and how to proactively educate prescriber and consumer on ways to manage (competitive DTP and better educated consumer

Package literature limitations

Points Person/manpower Advisor
Budgetany consorre

Budgetary concerns

• Developmental time

· Dev. Costs

nental time

Janel to put together/dair

Advisory panel to put together/develop program content
Should advisory/speaker panel include both psychs and PCPs

Will the psychs approve

How will manage care react (can we do something proactively . . . Tenn@are)

Does a scale exist to measure (i.e. Zung, Young Mania RS)

Limitation could be data capture (i.e., Walmart, Arkansas, formulary restrictions, etc.)

consider direct mail flu between Feb and May



- National symposia
- Regional/District symposia
- Territory programs
- Review articles in journal
- Audioconference series
- Redacted could fit in when appropriate
- Solicit MDMDA support